TISIDB

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass membrane protein Golgi apparatus, trans-Golgi network membrane Single-pass membrane protein Cytoplasmic vesicle, secretory vesicle Note=Located predominantly in the trans-Golgi network. Probably trafficks between the trans-Golgi network and the cell membrane via the secretory pathway.
Domain	PF15281 Consortin C-terminus
Function	Required for targeting of connexins to the plasma membrane.

> Gene Ontology [ TOP ]
Biological Process	GO:0007009 plasma membrane organization GO:0010921 regulation of phosphatase activity GO:0010923 negative regulation of phosphatase activity GO:0016311 dephosphorylation GO:0035303 regulation of dephosphorylation GO:0035305 negative regulation of dephosphorylation GO:0042996 regulation of Golgi to plasma membrane protein transport GO:0042998 positive regulation of Golgi to plasma membrane protein transport GO:0043001 Golgi to plasma membrane protein transport GO:0051222 positive regulation of protein transport GO:0051346 negative regulation of hydrolase activity GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:0090002 establishment of protein localization to plasma membrane GO:0090003 regulation of establishment of protein localization to plasma membrane GO:0090004 positive regulation of establishment of protein localization to plasma membrane GO:0090150 establishment of protein localization to membrane GO:1903076 regulation of protein localization to plasma membrane GO:1903078 positive regulation of protein localization to plasma membrane GO:1903729 regulation of plasma membrane organization GO:1903829 positive regulation of cellular protein localization GO:1904375 regulation of protein localization to cell periphery GO:1904377 positive regulation of protein localization to cell periphery GO:1904951 positive regulation of establishment of protein localization GO:1990778 protein localization to cell periphery
Molecular Function	GO:0019902 phosphatase binding GO:0071253 connexin binding
Cellular Component	GO:0005802 trans-Golgi network GO:0030133 transport vesicle GO:0031984 organelle subcompartment GO:0098791 Golgi subcompartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CNST and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CNST in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CNST in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.398	0.134
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.406	0.79
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.397	0.701
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.208	0.587
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.83	0.627
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.577	0.785
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.48	0.166
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.193	0.901
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.736	0.685
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.356	0.67
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.87	0.473
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.133	0.0203

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CNST in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	0	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	0	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CNST. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CNST. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CNST. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CNST. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CNST expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CNST and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CNST
Name	consortin, connexin sorting protein
Aliases	FLJ32001; PPP1R64; protein phosphatase 1, regulatory subunit 64; C1orf71; chromosome 1 open reading frame 71 ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CNST collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CNST